DETERMINATION OF PACLITAXEL AND METABOLITES IN MOUSE PLASMA, TISSUES, URINE AND FECES BY SEMIAUTOMATED REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY

被引:73
作者
SPARREBOOM, A [1 ]
VANTELLINGEN, O [1 ]
NOOIJEN, WJ [1 ]
BEIJNEN, JH [1 ]
机构
[1] SLOTERVAART HOSP,DEPT PHARM,1066 EC AMSTERDAM,NETHERLANDS
来源
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS | 1995年 / 664卷 / 02期
关键词
D O I
10.1016/0378-4347(94)00495-Q
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
We have developed and validated a sensitive and selective assay for the quantification of paclitaxel and its metabolites 6 alpha,3'-p-dihydroxypaclitaxel, 3'-p-hydroxypaclitaxel and 6 alpha-hydroxypaclitaxel in plasma, tissue, urine and faeces specimens of mice. Tissue and faeces were homogenized (approximately 0.1-0.2 g/ml) in bovine serum albumin (40 g/l) in water, and urine was diluted (1:5, v/v) in blank human plasma. Sample pretreatment involved liquid-liquid extraction of 200-1000 mu l of sample with diethyl ether followed by automated solid-phase extraction using cyano Bond Elut columns. 2'-Methylpaclitaxel was used as internal standard. The overall recovery of the sample pretreatment procedure ranged from 76 to 85%. In plasma, the lower limit of detection (LOD) and the lower limit of quantitation (LLQ) are 15 and 25 ng/ml, respectively, using 200 mu l of sample. In tissues, faeces and urine the LLQs are 25-100 ng/g, 125 ng/g and 25 ng/ml, respectively, using 1000 mu l (faeces: 200 mu l) of homogenized or diluted sample. The concentrations in the various biological matrices, for validation procedures spiked with known amounts of the test compounds, are read from calibration curves constructed in blank human plasma in the range 25-100 000 ng/ml for paclitaxel and 25-500 ng/ml for the metabolites. The accuracy and precision of the assay fall within the generally accepted criteria for bio-analytical assays.
引用
收藏
页码:383 / 391
页数:9
相关论文
共 27 条
[1]   A PHASE-I TRIAL OF TAXOL GIVEN BY A 6-HOUR INTRAVENOUS-INFUSION [J].
BROWN, T ;
HAVLIN, K ;
WEISS, G ;
CAGNOLA, J ;
KOELLER, J ;
KUHN, J ;
RIZZO, J ;
CRAIG, J ;
PHILLIPS, J ;
VONHOFF, D .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (07) :1261-1267
[2]  
CHANG A, 1992, P AN M AM SOC CLIN, V11, P293
[3]  
GREM JL, 1987, CANCER TREAT REP, V71, P1179
[4]  
GROTHAUS PG, 1993, J IMMUNOL METHODS, V158, P158
[5]  
HAMEL E, 1982, CANCER TREAT REP, V66, P1381
[6]   PHASE-II TRIAL OF TAXOL, AN ACTIVE-DRUG IN THE TREATMENT OF METASTATIC BREAST-CANCER [J].
HOLMES, FA ;
WALTERS, RS ;
THERIAULT, RL ;
FORMAN, AD ;
NEWTON, LK ;
RABER, MN ;
BUZDAR, AU ;
FRYE, DK ;
HORTOBAGYI, GN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (24) :1797-1805
[7]   TAXOL - MECHANISMS OF ACTION AND RESISTANCE [J].
HORWITZ, SB ;
LOTHSTEIN, L ;
MANFREDI, JJ ;
MELLADO, W ;
PARNESS, J ;
ROY, SN ;
SCHIFF, PB ;
SORBARA, L ;
ZEHEB, R .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1986, 466 :733-744
[8]   PHARMACOKINETICS OF PACLITAXEL AND METABOLITES IN A RANDOMIZED COMPARATIVE-STUDY IN PLATINUM-PRETREATED OVARIAN-CANCER PATIENTS [J].
HUIZING, MT ;
KEUNG, ACF ;
ROSING, H ;
VANDERKUIJ, V ;
HUININK, WWT ;
MANDJES, IM ;
DUBBELMAN, AC ;
PINEDO, HM ;
BEIJNEN, JH .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (11) :2127-2135
[9]   STEADY-STATE PLASMA-CONCENTRATIONS AND EFFECTS OF TAXOL FOR A 250-MG/M(2) DOSE IN COMBINATION WITH GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH OVARIAN-CANCER [J].
JAMISDOW, CA ;
KLECKER, RW ;
SAROSY, G ;
REED, E ;
COLLINS, JM .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 33 (01) :48-52
[10]   STABILITY PROBLEMS WITH TAXOL IN MOUSE PLASMA DURING ANALYSIS BY LIQUID-CHROMATOGRAPHY [J].
LESLIE, J ;
KUJAWA, JM ;
EDDINGTON, N ;
EGORIN, M ;
EISEMAN, J .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1993, 11 (11-12) :1349-1352